MET exon 14 skipping mutation occurs in approximately 3% of lung adenocarcinoma and 2.3% of other lung cancer subtypes and is mutually exclusive with other known driver gene mutations such as EGFR, KRAS, and HER2, suggesting its potential as a true oncogenic driver site (6, 7). This evidence concerns the gene MET and lung adenocarcinoma.